Skip to main content
Medicamen Biotech Ltd. logo

Medicamen Biotech Ltd. — Investor Relations & Filings

Ticker · MEDICAMEQ ISIN · INE646B01010 LEI · 894500T0ULD27B7W4Y03 BSE.NS Manufacturing
Open in API
Filings indexed 277 across all filing types
Latest filing 2023-05-30 Capital/Financing Update
Country IN India
Listing BSE.NS MEDICAMEQ

About Medicamen Biotech Ltd.

https://www.medicamen.com/

Medicamen Biotech Ltd. specializes in the research, development, and manufacturing of a diverse range of pharmaceutical formulations. The company operates manufacturing facilities compliant with international quality standards, including WHO-GMP. Its product portfolio encompasses various therapeutic segments such as oncology, cardiology, central nervous system, and anti-infectives, delivered through dosage forms like tablets, capsules, and liquid orals. A significant strategic focus is placed on its specialized oncology division, which develops complex generic formulations. The company serves global markets, leveraging its research and development capabilities to provide high-quality healthcare solutions. Its operations are supported by dedicated R&D centers focused on formulation development and process chemistry.

Recent filings

Filing Released Lang Actions
Statement of deviation(s) or variation(s) under Reg. 32
Capital/Financing Update Classification · 95% confidence The document is a statement submitted to stock exchanges regarding deviation or variation in the utilization of funds raised through a preferential issue, as per SEBI regulations. It includes details about the amount raised, the quarter ended, and confirms no deviation in fund utilization. It is a regulatory compliance disclosure related to capital raising and fund usage, not a full financial report or earnings release. The document length is short (4267 characters) and it is a formal statement of fund utilization deviation under SEBI Listing Obligations, which fits the category of Capital/Financing Update (CAP).
2023-05-30 English
Related Party Transactions
Regulatory Filings Classification · 95% confidence The document is a disclosure of related party transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed tables of related party transactions for the half year ended March 31, 2023, including transaction types, values, approvals, and balances. The document is 7293 characters long, which is substantive and contains actual financial data related to related party transactions. It is not an announcement of a report, nor a certification or attestation. The content fits the category of Regulatory Filings (RNS) as it is a regulatory disclosure under SEBI regulations but does not fit into other specific categories like Annual Report, Interim Report, or Management Reports. Therefore, the best classification is Regulatory Filings (RNS).
2023-05-30 English
Dividend
Regulatory Filings
2023-05-29 English
Dividend Updates
Regulatory Filings
2023-05-29 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed announcement from Medicamen Biotech Limited regarding the outcome of a Board Meeting held on May 29, 2023. It includes approval of the Audited Financial Results (Standalone and Consolidated) for the quarter and year ended March 31, 2023. The document references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and includes financial tables with detailed figures for income, expenses, profit, and other financial metrics. It also mentions the appointment of auditors and declaration of a final dividend. The presence of detailed audited financial results for a full fiscal year, along with comprehensive financial data and notes, indicates this is a full Annual Report type filing rather than a brief earnings release or a simple announcement. The document length (15,000 characters) and the inclusion of detailed financial statements confirm it is not merely an announcement of a report but the report itself. Therefore, the filing type is Annual Report (10-K). FY 2023
2023-05-29 English
Board Meeting — MEDICAMEN BIOTECH LIMITED has informed the Exchange about Board Meeting to be held on 29-May-2023 to consider and approve the Yearly Audited Financial results of the Company for the p…
Regulatory Filings
2023-05-22 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.